DuPont H L, Sullivan P, Evans D G, Pickering L K, Evans D J, Vollet J J, Ericsson C D, Ackerman P B, Tjoa W S
JAMA. 1980 Jan 18;243(3):237-41.
The efficacy of a daily dosage regimen of subsalicylate bismuth in preventing or reducing the severity of diarrhea among young healthy adults was evaluated in a double-blind, randomized, placebo-controlled trial. Diarrhea developed in 14 (23%) of 62 students receiving subsalicylate bismuth compared with 40 (61%) of 66 students taking a placebo. The protective effect of subsalicylate bismuth was apparent within a day or two of the study onset and became more obvious as the number of days at risk increased. The students treated with subsalicylate bismuth experienced fewer intestinal complaints and were less likely to pass soft or watery stools of any number. Once diarrhea occurred, enteropathogens were less commonly identified in stools of students receiving subsalicylate bismuth (33%) compared with placebo (71%). Subsalicylate bismuth was well tolerated by students during the 21-day trial.
在一项双盲、随机、安慰剂对照试验中，评估了次水杨酸铋每日剂量方案在预防或减轻年轻健康成年人腹泻严重程度方面的疗效。接受次水杨酸铋治疗的62名学生中有14名（23%）出现腹泻，而服用安慰剂的66名学生中有40名（61%）出现腹泻。次水杨酸铋的保护作用在研究开始后的一两天内就很明显，并且随着风险天数的增加而变得更加明显。接受次水杨酸铋治疗的学生肠道不适较少，排出任何数量软便或水样便的可能性也较小。一旦发生腹泻，与安慰剂组（71%）相比，接受次水杨酸铋治疗的学生粪便中检出肠道病原体的情况较少（33%）。在为期21天的试验中，学生对次水杨酸铋耐受性良好。
